Emced Khalil

The efficacy of Pharmacomechanical catheter-directed thrombolysis in patients with concomitant deep vein thrombosis and pulmonary embolism: A retrospective analysis of 26 patients

This study aimed to analyze the impact of pharmacomechanical catheter-directed thrombolysis (PCDT) on venous patency, pulmonary artery systolic pressure, O2 saturation and in-hospital mortality in patients admitted for deep vein thrombosis (DVT) and concomitant pulmonary embolism (PE). Twenty-six patients presenting with DVT and concomitant non-massive PE were analyzed in aretrospective manner. All subjects underwent PCDT with urokinase. The primary end-point of this study was the difference in pre-and post PCDT sPAP and O2 saturation. Duplex ultrasonography performed before discharge revealed complete recanalization of the compromised vein in 21 (80%) of the subjects. Duplex ultrasonography performed 3 months after discharge showed restenosis of the compromised vein in only two patients (8%). There was partial recanalization in 5 patients (20%). A significant improvement in SaO2 was observed following the infusion of urokinase compared to baseline values (94.5±1.1 % vs. 98.6±0.5 %, p

PDF

___

1. Giordano NJ, Jansson PS, Young MN, et al. Epidemiology, Pathophysiology, Stratification, and Natural History of Pulmonary Embolism. Tech Vasc Interv Radiol. 2017;20:135-40.
2. Anderson Jr FA, Zayaruzny M, Heit JA, et al. Estimated annual numbers of US acute‐care hospital patients at risk for venous thromboembolism. Am J Hematol. 2007;82:777-82.
3. Smith SB, Geske JB, Kathuria P, et al. Analysis of national trends in admissions for pulmonary embolism. Chest. 2016;150:35-45.
4. Crous-Bou M, Harrington LB, Kabrhel C. Environmental and Genetic Risk Factors Associated with Venous Thromboembolism. Semin Thromb Hemost. 2016;42:808-20.
5. Tritschler T, Kraaijpoel N, Le Gal G, et al. Venous thromboembolism: advances in diagnosis and treatment. JAMA. 2018;320:1583-94.
6. Comerota AJ, Grewal N, Martinez JT, et al. Postthrombotic morbidity for iliofemoral deep vein thrombosis. J Vasc Surg. 2012;55:768-73.
7. Baekgaard N, Broholm R, Just S, Jet al. Long-term results using catheterdirected thrombolysis in 103 lower limbs with acute iliofemoral venous thrombosis. Eur J Vasc Endovasc Surg. 2010;39:112-7.
8. Schulman S, Ageno W, Konstantinides SV. Venous thromboembolism: Past, present and future. Thromb Haemost. 2017;117:1219-29.
9. Battinelli EM, Murphy DL, Connors JM. Venous thromboembolism overview. Hematol Oncol Clin North Am. 2012;26:345-67, ix.
10. Beckman MG, Hooper WC, Critchley SE, et al. Venous thromboembolism: a public health concern. Am J Prev Med. 2010;38:S495-501.
11. Forster A, Wells P. Tissue plasminogen activator for the treatment of deep venous thrombosis of the lower extremity: a systematic review. Chest. 2001;119:572-9.
12. Turpie AG, Levine MN, Hirsh J, et al. Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis. Results of a randomized trial. Chest. 1990;97:172-5.
13. Miller DJ, Simpson JR, Silver B. Safety of thrombolysis in acute ischemic stroke: a review of complications, risk factors, and newer technologies. Neurohospitalist. 2011;1:138-47.
14. Chiarello MA, Sista AK. Catheter-Directed Thrombolysis for Submassive Pulmonary Embolism. Semin Intervent Radiol. 2018;35:122-8.
15. Güneş Y, Sincer I, Erdal E. Catheter-directed intra-arterial thrombolysis for lower extremity arterial occlusions. Anatol J Cardiol. 2019;22:54-9.
16. Avgerinos ED, Saadeddin Z, Abou Ali AN, et al. A meta-analysis of outcomes of catheter-directed thrombolysis for high- and intermediate-risk pulmonary embolism. J Vasc Surg Venous Lymphat Disord. 2018;6:530-40.
17. Watson L, Broderick C, Armon MP. Thrombolysis for acute deep vein thrombosis. Cochrane Database Syst Rev. 2014:Cd002783.
18. Kucher N, Boekstegers P, Müller OJ, et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediaterisk pulmonary embolism. Circulation. 2014;129:479-86.
19. Avgerinos ED, Chaer RA. The ATTRACT iveness of catheter-directed thrombolysis. J Vasc Surg Venous Lymphat Disord. 2018;6:303.
20. Enden T, Haig Y, Kløw NE, et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet. 2012;379:31-8.
21. Baran Ç, Çakıcı M, Özçınar E, et al. Comparison of different venous accesses through catheter-directed thrombolysis procedures in patients with acute deep vein thrombosis. Turk J Vasc Surg. 2017;26:080-4.